<DOC>
	<DOCNO>NCT00895505</DOCNO>
	<brief_summary>This clinical trial investigate hypothesis D-Dimer test successfully use tailor duration OAT patient unprovoked episode deep venous thrombosis ( DVT ) use prospective , randomize , control design .</brief_summary>
	<brief_title>D-Dimer Guided Oral Anticoagulant Treatment ( OAT )</brief_title>
	<detailed_description>After first episode acute deep venous thrombosis ( DVT ) risk recurrence relatively high clinical consequence important . Therefore , secondary prophylaxis use oral anticoagulant treatment ( OAT ) usually establish patient . This treatment effectively reduce risk recurrence induces increase risk bleeding . Major bleed complication expect ~2 % patient-years . Therefore , current recommendation limit OAT period 3 12 month . After stop OAT , however , ~10 % patient initial episode unprovoked DVT develop recurrent event within 1 year . This group patient may benefit prolonged OAT . The result 2 independent observational study show significantly high risk recurrence patient show increased level D-Dimer withdrawal OAT . D-Dimer biomarker indicate fibrin formation follow fibrinolysis . Based data hypothesize D-Dimer test successfully use tailor duration OAT patient unprovoked episode DVT . This clinical trial investigate hypothesis use prospective , randomize , control design .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Fibrin fragment D</mesh_term>
	<criteria>To enrol study , patient must : objectively confirm first episode unprovoked VTE VTE minor transient risk factor . Minor transient risk factor include 6 week estrogen therapy , prolong air travel ( i.e. , &gt; 6 hour ) , pregnancy , less marked leg injury immobilization without injury surgical intervention schedule receive oral anticoagulant treatment least 3 month willing randomize willing participate full duration study pregnancy breast feed contraindication OAT ( i.e. , intracranial hemorrhage , subarachnoid hemorrhage , hemorrhagic stroke ) age &lt; 18 year presence antiphospholipid antibody thrombophilic risk factor require longterm OAT ( i.e. , antithrombin deficiency , hereditary PC deficiency ) poor patient compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>DVT</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>D-Dimer</keyword>
	<keyword>thrombophilia</keyword>
	<keyword>secondary prophylaxis</keyword>
	<keyword>secondary prophylaxis use oral anticoagulant treatment ( OAT )</keyword>
	<keyword>high risk recurrence patient show increased level</keyword>
	<keyword>D-Dimer withdrawal OAT</keyword>
	<keyword>D-Dimer-based treatment</keyword>
</DOC>